Its shares are up 134% year-to-date. The stock soared in late February after the FDA backed its weight loss drug Qnexa. Arena also develops drugs for cardiovascular, central nervous system, inflammatory and metabolic diseases. Up 71% …
VIVUS, Inc. (NASDAQ: VVUS) is in the news this morning after entering into an agreements with a select group of institutional investors to sell 6,889,098 shares of its common stock. Rather than this being a public secondary offing, it …
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is VIVUS Inc. (VVUS). This Medical – Biomedical/Genetics stock has actually seen loss estimates narrow over the past month for …
Vivus Inc. VVUS, -3.72% shares rose 4.6% in premarket trade Monday after the company said it would regain the right to commercialize and promote erectile dysfunction drug Stendra in Africa, the Middle East, Turkey and Russia from Sanofi …
VVUS): The maker of diet drug Qsymia is upgraded to Outperform from Market Perform at Cowen. As a result its shares, up 8.64% in yesterday's down market, are adding to gains ahead of the open. VMware (NYSE:VMW): FBN Securities …
DALLAS, Oct. 21, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you …
Investors can receive FREE Stock Alerts by visiting doubleinstocks.com at the following link: http://www.doubleinstocks.com Today's alerts include: Zamage Digital Art, Inc. (Other OTC: ZMGD.PK), VIVUS Inc. …
A year ago, they were trading at $1.04. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is VIVUS Inc. (NASDAQ: VVUS). This Medical – Biomedical/Genetics stock has actually seen loss estimates narrow over the past …